New initiative with the Synthetic Biology CDT
About Oxford Centre
This author has yet to write their bio.Meanwhile lets just say that we are proud Oxford Centre contributed a whooping 69 entries.
Entries by Oxford Centre
The Centre is pleased to announce the appointment of Professor Xin Lu as Co-Director of the Centre.
Today at the NCRI Annual Conference Professor Simon Leedham was awarded the Cancer Research UK Future Leaders in Cancer Research Prize. Simon is a Cancer Research UK Clinician Scientist Fellow at the Wellcome Trust Centre for Human Genetics. His research has made important advances in the cell biology and molecular pathogenesis of gastrointestinal cancers and […]
Professor Nicola Sibson of the Department of Oncology has been awarded a grant worth almost £200,000 by research charity Breast Cancer Now to fund cutting-edge research to uncover novel treatment combinations to control breast cancer that has spread to the brain.
John Findlay wins Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS) prize for his presentation ’Staging gastric cancer with 18F-FDG PET-CT identifies frequent unsuspected metastases and patients of high risk of incurable disease, early recurrence and death’
Today a new drug will become available for patients with bowel cancer as part of a national clinical trial; based on a scientific discovery made only two years ago at the University of Oxford.
Professor Tim Maughan, Professor of Clinical Oncology at the University of Oxford and Principal Lead of the S:CORT Consortium said: “This research emphasises how a collaborative approach can give significant insight into bowel cancer disease biology, but also to begin to translate this knowledge into clinically-relevant applications. As part of the work of the S:CORT consortium, we will now focus on making sure that the research is put into practice so that it can become part of the standard of care for patients.”
FOXFIRE Combined Analysis indicates no benefit in overall survival from adding selective internal radiotherapy [SIRT] to first-line oxaliplatin-based chemotherapy for metastatic colorectal cancer. Secondary analyses confirm improved control of liver metastases with liver-directed SIRT and show clinical benefit in patients with liver metastases originating from difficult-to-treat right-sided colon cancer.
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK today.
Smokers treated for breast cancer have much higher risks than non-smokers of developing lung cancer or heart attack as a result of radiotherapy – according to a new study lead by the University of Oxford published in the Journal of Clinical Oncology.